ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.1% – Should You Sell?

ADMA Biologics Inc (NASDAQ:ADMA) shares fell 8.1% on Wednesday . The stock traded as low as $14.87 and last traded at $14.8350. 3,540,730 shares changed hands during trading, an increase of 28% from the average session volume of 2,770,198 shares. The stock had previously closed at $16.15.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Finally, Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $32.00.

ADMA Biologics Trading Down 8.0%

The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16. The firm has a market cap of $3.54 billion, a price-to-earnings ratio of 24.76 and a beta of 0.51. The company has a 50-day moving average price of $16.55 and a 200 day moving average price of $16.69.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. During the same period in the previous year, the firm earned $0.46 earnings per share. ADMA Biologics’s quarterly revenue was up 18.4% on a year-over-year basis. As a group, research analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. This represents a 2.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steve Elms bought 7,000 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the purchase, the director directly owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 3.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds have recently modified their holdings of the stock. Summit Securities Group LLC purchased a new position in ADMA Biologics in the fourth quarter valued at about $29,000. Salomon & Ludwin LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth about $25,000. Rothschild Investment LLC raised its stake in shares of ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares in the last quarter. Optima Capital LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter valued at about $36,000. Finally, Clearstead Advisors LLC grew its stake in shares of ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 795 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.